- Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
- Immix Biopharma on Track to Dose NXC-201 Patients in United States
- Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
- Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
- Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
- Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
- Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
- Immix Biopharma Announces Proposed Public Offering of Common Stock
- Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products
- Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board
More ▼
Key statistics
As of last trade, Immix Biopharma Inc (IMMX:NAQ) traded at 2.41, 55.16% above the 52 week low of 1.55 set on Aug 17, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.44 |
---|---|
High | 2.45 |
Low | 2.26 |
Bid | 2.39 |
Offer | 2.42 |
Previous close | 2.25 |
Average volume | 102.52k |
---|---|
Shares outstanding | 26.41m |
Free float | 15.44m |
P/E (TTM) | -- |
Market cap | 59.43m USD |
EPS (TTM) | -0.9263 USD |
Data delayed at least 15 minutes, as of May 28 2024 15:50 BST.
More ▼